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STRATEGIES TO IMPROVE PRODUCTIVITY OF CHO-S CELLS EXPRESSING AN
ANTI-TNFα MAB WITH BIOSIMILAR POTENTIAL
Ana Moro, Mateus Luchese, Wagner Quintilio, Lilian Tsuruta, Mariana Lopes dos Santos
Laboratory of Biopharmaceuticals in Animal Cells, Instituto Butantan, São Paulo, SP, Brazil
ana.moro@butantan.gov.br

ABSTRACT
ADABUT CELL LINE GENERATION

CULTURE CONDITIONS

Tumor necrosis factor alpha (TNFα) is a proinflammatory cytokine that mediates the homeostasis of
immune responses; its exacerbated production is associated with the pathogenesis of autoimmune and
chronic inflammatory diseases. TNFα antagonists have revolutionized the treatment of inflammatory
conditions such as rheumatoid arthritis and Crohn’s disease. Currently, a worldwide race is on stage for
the production of biosimilars moved by patent expiration of monoclonal antibodies (mAbs), such as
anti-TNFα adalimumab. This project is based on the first development stage for an adalimumab
biosimilar candidate with potential for national production through the generation of a productive and
stable cell line and assessment of its functionality. The robotic system ClonePix-FL was used for
screening and isolation of colonies from transfected CHO-S stable pools plated in semisolid medium.
Selected clones were expanded based on growth and productivity (Figure 1-2). Purified mAbs from
different clones were tested for binding and functional activity. The binding affinity of the denominated
adabut clones to TNFα (Figure 3) and FcRs, tested by surface plasmon resonance, did not differ
statistically when compared to reference adalimumab. One functional activity assay demonstrated the
antibody neutralization capacity of the cytotoxicity induced by TNFα in L929 murine fibroblasts. A
second assay confirmed adabut as an antagonist of the TNFα activity by the inhibition of the cell
adhesion molecule expression in HUVEC cultures (figure 4). The binding kinetics and functional analysis
performed suggest a potential for further development of adabut as a biosimilar.

The process of the cell line development for adabut generated data consisting of cell growth/viability,
volumetric and specific productivity, antigen binding kinetics, functional assays and long-term stability,
from which 3 clones were selected. One clone (123) was top ranked and 2 others (70 and 225) showed
equivalent performance. To increase the basal productivity of clone 123, 0.6g/L, we run 24
experiments evaluating 6 basal media and 9 supplements from 4 vendors. A temperature shift to 32 C
on day 6 was applied on some conditions. The experiments were conducted in shaker flasks along 14
days or while cell viability was above 60%. The flasks were sampled daily for cell counting/viability by
Vi-Cell XR cell counter and glucose monitoring. Samples were stored for additional metabolites and
antibody concentration assessment. By testing 24 different fed-batch (FB) strategies we were able to
increase the volumetric clone productivity while maintaining structure integrity. Table 1 shows the 7
best conditions for clone 123, with titer/IVCC shown on Figure 5. The mAbs were purified by protein-A
capture from clarified supernatants taken on days 14, 16 or 17 of FB cultures. Analyses consisted of
SDS-PAGE, SEC-HPLC, IEF and IEX-HPLC (Figure 6), in comparison to the reference. The FB condition 2
was elected to cultivate the 3 top clones (Figure 7). At day 14 the duplicate runs were stopped,
presenting viability over 95%. The clarified supernatants were fully purified through protein A capture,
acid pH hold, Q and S sepharose resins. The mAb integrity was evaluated by SDS-PAGE (reduced and
non-reduced), IEF, SEC-HPLC and IEX-HPLC. The purity was above 99-100% for all samples. IEX-HPLC
and IEF analyses allowed the identification of fractions very similar to the reference.

RESULTS
Table 1- Best culture conditions for clone 123 at FB in SF
4345 clones
460 clones
264 clones

Condition

96-well µplates
1

24-well µplates

114 clones

6-well µplates

64 clones

T25

40 clones

SF125

33 clones

Fed-Batch

2
3
4
5

Figure 1: Expansion of the adabut selected clones based on growth
and productivity. The clones were expanded in 24 and 6-wells plates,
T25 and SF125 flasks, as confluence showed >70% and/or were
chosen along the process based on specific productivity. The
productivity was measured by ELISA or SPR (Surface Plasmon
Resonance) in a BIAcore T-200 system (GE Healthcare).
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Figure 2: Batch - with glucose supplementation experiment of 33 selected adabut clones in SF-125.
Glucose was added to the cell culture on days 3 (4 g/L),
5 (4 g/L) and 7 (6 g/L). The concentration of adabut
mAb in the supernatant was measured by SPR

Figure 3: Binding affinity of 33 adabut clones to
recombinant TNFα. The graphic represents the
relationship between constants of association (ka),
expressed in 1/M.s, and dissociation (kd), in s-1
determined by SPR in two independent experiments.
The diagonal lines correspond to the affinity constant
(KD), expressed in nM. Highlighted in red is the result
obtained for the reference adalimumab
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Figure 4: Inhibition of the
Endothelial cell Leukocyte
Adhesion Molecule-1 (ELAM1) expression by HUVECs in
response
to
anti-TNFα
treatment. The induction of
ELAM-1 expression by HUVEC
was verified by cell surface
fluorescence with a FITCconjugated
anti-ELAM-1
antibody. (a) HUVEC as
negative control and (b)
HUVEC/TNFα as positive
control of the assay. (c)
Example of purified antiTNFα adabut mAb and (d)
adalimumab. Scale 100 µm.
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Medium (Gln) + Feed
(regimen)
M 1 (8mM) + F A/F B (day
3 to the end)
M 2 (8mM) + F A/F B (day
3 to the end) TºC shift
M 3 (6mM) +F 1 5% (even
alternate days)
M 3 (4mM) + F 1 5%
(even alternate days)
M 3 (8mM) + F 1 5%
(asymmetric feed)
M 3 (8mM) + F 1 5% (day
3 to the end – 5 to 7.5%)
M 4 (8mM) + F A/F B (day
3 to the end)

Max viable cell
density (x106)/mL
28.95 (day 11)

Days of culture
Glucose
Max lactate
(% viability)
min-max (g/L)
(g/L)
14 (93.5)
0.06-6.76
2.70 (day 8)

Max ammonia Titer (mg/mL)
(mM)
by SPR (day 14)
5.47 (day 4)
2.75

23.66 (day 8)

14 (97)

0.07-5.79

2.11 (day 6)

1.25 (day 3)

2.39

13.75 (day 10)

14 (79.7)

0.5-5.49

1.48 (day 7)

5.39 (day 14)

2.36

14.09 (day 10)

14 (83.6)

0.76-5.34

1.34 (day 3)

5.02 (day 12)

1.77

12.02 (day 8)

14 (73.2)

0.6-5.38

1.72 (day 7)

6.77 (day 8)

1.27

12.51 (day 7)

14 (64.5)

0.5-5.56

1.96 (day 8)

5.71 (day 5)

1.18

40.25 (day 11)

14 (89.8)

0.07-5.95

2.35 (day 14)

2.55 (day 9)

1.14

Figure 5: Adabut clone 123 titer in relation to cellular density
along the FB cultivation. Seven different combinations of
basal media and feeds were followed for 14 days. An antihuman Fc immobilized sensor was used for SPR titer
evaluation

Figure 7: Adabut titers
measured along 14
days of FB cultivation
on condition 2 for 3
top clones. A proteinA immobilized sensor
was used for SPR titer
evaluation. The letter
B stands for duplicate
runs.

Figure 6: IEX-HPLC from protein-A purifed adabut clone 123
obtained by variations of feeding strategy, in comparison to
the reference

